Literature DB >> 7585188

Evidence of an X-linked or recessive genetic component to prostate cancer risk.

K R Monroe1, M C Yu, L N Kolonel, G A Coetzee, L R Wilkens, R K Ross, B E Henderson.   

Abstract

We used data from a population-based cohort study of blacks, Hispanics, Japanese and whites to examine the frequency of prevalent prostate and breast cancer by family history status of first-degree relatives (parents and siblings). Independent of race, the age-adjusted relative risk for prevalent prostate cancer in subjects with affected brothers was approximately two times that in subjects with affected fathers (P < 0.00005). No such excess risk for breast cancer was observed among subjects with affected sisters compared to those with affected mothers (age- and race-adjusted relative risk = 1.10, P = 0.34). The magnitude of the relative risk for prostate cancer in sibling- versus parent-affected groups was significantly different from that of the comparable relative risk for breast cancer (P < 0.00005). An excess risk of prostate cancer in men with affected brothers compared to those with affected fathers is consistent with the hypothesis of an X-linked, or recessive, model of inheritance.

Entities:  

Mesh:

Year:  1995        PMID: 7585188     DOI: 10.1038/nm0895-827

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  38 in total

1.  Segregation analyses of 1,476 population-based Australian families affected by prostate cancer.

Authors:  J Cui; M P Staples; J L Hopper; D R English; M R McCredie; G G Giles
Journal:  Am J Hum Genet       Date:  2001-04-11       Impact factor: 11.025

2.  Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4.

Authors:  K A Goddard; J S Witte; B K Suarez; W J Catalona; J M Olson
Journal:  Am J Hum Genet       Date:  2001-04-13       Impact factor: 11.025

3.  A genome screen of multiplex sibships with prostate cancer.

Authors:  B K Suarez; J Lin; J K Burmester; K W Broman; J L Weber; T K Banerjee; K A Goddard; J S Witte; R C Elston; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

4.  A genomic scan of families with prostate cancer identifies multiple regions of interest.

Authors:  M Gibbs; J L Stanford; G P Jarvik; M Janer; M Badzioch; M A Peters; E L Goode; S Kolb; L Chakrabarti; M Shook; R Basom; E A Ostrander; L Hood
Journal:  Am J Hum Genet       Date:  2000-05-19       Impact factor: 11.025

5.  Evidence for a prostate cancer-susceptibility locus on chromosome 20.

Authors:  R Berry; J J Schroeder; A J French; S K McDonnell; B J Peterson; J M Cunningham; S N Thibodeau; D J Schaid
Journal:  Am J Hum Genet       Date:  2000-05-16       Impact factor: 11.025

6.  Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer.

Authors:  C H Bock; J M Cunningham; S K McDonnell; D J Schaid; B J Peterson; R J Pavlic; J J Schroeder; J Klein; A J French; A Marks; S N Thibodeau; E M Lange; K A Cooney
Journal:  Am J Hum Genet       Date:  2001-02-06       Impact factor: 11.025

7.  Estimation of sibling recurrence-risk ratio under single ascertainment in two-child families.

Authors:  P Wickramaratne; S Hodge
Journal:  Am J Hum Genet       Date:  2001-03       Impact factor: 11.025

8.  X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Authors:  Yang Liu; Lizhong Wang; Pan Zheng
Journal:  Trends Genet       Date:  2010-04-29       Impact factor: 11.639

9.  Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance.

Authors:  Sanna Pakkanen; Agnes B Baffoe-Bonnie; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Snehal Deshmukh; Liang Ou; Joan E Bailey-Wilson; Johanna Schleutker
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

10.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.